Venpa 25 mg (Capsule)
Unit Price: ৳ 9.00 (3 x 10: ৳ 270.00)
Strip Price: ৳ 90.00
Medicine Details
Category | Details |
---|---|
Generic | Pregabalin |
Company | Maks drug limited |
Also available as |
Indications
- Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
- Postherpetic neuralgia (PHN)
- Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
- Fibromyalgia
- Neuropathic pain associated with spinal cord injury
Pharmacology
- Structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)
- Binds with high affinity to the alpha2-delta site in central nervous system tissues
Dosage
- Maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min
- Recommended dose of Pregabalin is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min
- Recommended dose of Pregabalin for management of fibromyalgia in adults is 300 to 450 mg/day
- Recommended dose range of Pregabalin for neuropathic pain associated with spinal cord injury in adults is 150 to 600 mg/day
- Dosage should begin at 50 mg three times a day (150 mg/day) for diabetic peripheral neuropathy in adults
Administration
- Route of administration: Oral route
- Pregabalin CR tablet should be administered after an evening meal
- When discontinuing both Pregabalin and Pregabalin CR, it should be gradually tapered over a minimum of 1 week
Interaction
- Venpa is unlikely to be involved in significant pharmacokinetic drug interactions
Contraindications
- Contraindicated in patients with known hypersensitivity to Pregabalin or any of its components
Side Effects
- Most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal
- Most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite
Pregnancy & Lactation
- No adequate and well-controlled studies with pregabalin in pregnant women
- Small amounts of pregabalin have been detected in the milk of lactating women
Precautions & Warnings
- Angioedema can occur and may be associated with life threatening respiratory compromise requiring emergency treatment
- Venpa should be withdrawn gradually over a minimum of 1 week
- Venpa may cause peripheral edema
- Caution should be exercised when coadministering Venpa and thiazolidinedione antidiabetic agents
Use in Special Populations
- Safety and effectiveness in pediatric patients have not been established for the management of neuropathic pain
- Safety and effectiveness of Venpa extended-release tablet in pediatric patients have not been established
Overdose Effects
- Signs and symptoms are reduced consciousness, depression/anxiety, confusional state, agitation and restlessness
- Seizures and heart block have also been reported
- No specific antidote
Therapeutic Class
- Adjunct anti-epileptic drugs
- Primary anti-epileptic drugs
Storage Conditions
- Keep in a cool & dry place (below 30°C), protected from light & moisture
Chemical Structure
- Molecular Formula: C8H17NO2
Common Questions about Venpa 25 mg Capsule
- Venpa 25 mg Capsule is an anticonvulsant and is considered to be the first-line of treatment for neurotic pain, shingles, seizures and fibromyalgia
- Venpa 25 mg Capsule should be taken till the time you see an improvement in your health conditions
- Venpa 25 mg Capsule should be taken after food in a prescribed dosage
Common Tips
- Venpa 25 mg Capsule should be taken as per the dose and duration prescribed by your doctor
- Venpa 25 mg Capsule may cause sleepiness. Do not drive or do anything requiring concentration until you know how it affects you
- Venpa 25 mg Capsule may cause blurring or loss of vision. Inform your doctor immediately if you notice any vision changes
Related Brands
- Pregafast 75 mg (Capsule) - desh-pharmaceuticals-ltd
- Pregafast 50 mg (Capsule) - desh-pharmaceuticals-ltd
- PG CR 165 mg (Tablet (Controlled Release)) - eskayef-pharmaceuticals-ltd
- PG CR 82.5 mg (Tablet (Controlled Release)) - eskayef-pharmaceuticals-ltd
- Gabaglen 50 mg (Capsule) - chemist-laboratories-ltd